<DOC>
	<DOCNO>NCT00977938</DOCNO>
	<brief_summary>The DAPT Study double blind randomize control trial intend determine appropriate duration dual antiplatelet therapy ( combination aspirin second anti-clotting medication ) well safety effectiveness dual antiplatelet therapy protect patient stent thrombosis major adverse cardiovascular cerebrovascular event ( MACCE ) follow implantation drug-eluting coronary stent . Similar analysis conduct small cohort bare metal coronary stent - treated subject .</brief_summary>
	<brief_title>The Dual Antiplatelet Therapy Study ( DAPT Study )</brief_title>
	<detailed_description>Subjects ischemic heart disease due stenotic lesion either native coronary artery coronary artery bypass graft undergo percutaneous coronary intervention ( PCI ) stent placement contraindication prolong dual antiplatelet therapy eligible enrol study . All enrolled subject undergo PCI stent placement . All enrolled subject treat either FDA-approved drug elute stent ( ) ( DES ) FDA-approved bare metal stent ( ) ( BMS ) ( per respective Instructions Use ) assign 12 month open label FDA-approved thienopyridine treatment addition aspirin . Operators select thienopyridine accord package insert . Thienopyridine treatment dose accord standard practice prescribe information select medication . Aspirin treatment 75-325 mg first 6 month procedure 75-162 mg subsequently , continue indefinitely . All DES BMS subject treat 12 month dual antiplatelet therapy post index procedure event free per protocol eligible randomization either placebo ( 12 DAPT Study arm ) additional 18 month thienopyridine treatment ( 30 DAPT Study arm ) . Both arm continue aspirin therapy . Up four ( 4 ) separate post-market approval study allow incorporate randomize design DAPT Study subset subject may contribute DAPT Study analyse .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria ( Enrollment ) : 1 . Subject &gt; 18 year age . 2 . Subjects undergo percutaneous intervention stent deployment ( w/in 24 hour ) . 3 . Subjects without know contraindication dual antiplatelet therapy least 30 month enrollment stent implantation . 4 . The subject consent participate authorize collection release medical information sign `` Patient Informed Consent Form '' . The informed consent valid duration trial subject withdraws . Inclusion Criterion ( Randomization 12 month ) : 1 . Subject , 12 month , free death , MI , stroke , repeat coronary revascularization , major bleeding , stent thrombosis compliant dual antiplatelet therapy follow stent implantation . Exclusion Criteria ( Enrollment ) : 1 . Index procedure stent placement stent diameter &lt; 2.25 mm &gt; 4.0 mm . 2 . Pregnant woman . 3 . Planned surgery necessitate discontinuation antiplatelet therapy within 30 month follow enrollment . 4 . Current medical condition life expectancy le 3 year . 5 . Concurrent enrollment another device drug study whose protocol specifically exclude concurrent enrollment involve blind placement DES BMS include DAPT Study device . The subject may enrol DAPT Study . 6 . Subjects warfarin similar anticoagulant therapy . 7 . Subjects hypersensitivity allergies one drug component indicate Instructions Use device implant . 8 . Subjects unable give inform consent . 9 . Subject treat DES BMS index procedure . Exclusion Criteria ( Randomization 12 month ) : 1 . Pregnant woman . 2 . Subject switch thienopyridine type dose within 6 month prior randomization . 3 . Percutaneous coronary intervention cardiac surgery 6 week post index procedure randomization . 4 . Planned surgery necessitate discontinuation antiplatelet therapy within 21 month follow randomization . 5 . Current medical condition life expectancy le 3 year . 6 . Subjects warfarin similar anticoagulant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Zotarolimus</keyword>
	<keyword>Bare Metal Stent</keyword>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Clinical Events Committee</keyword>
	<keyword>Dual antiplatelet therapy</keyword>
	<keyword>Harvard Clinical Research Institute</keyword>
	<keyword>Major Adverse Cardiac Cerebral Event</keyword>
	<keyword>Major Bleeding</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Stent placement</keyword>
	<keyword>Stent Thrombosis</keyword>
	<keyword>Thienopyridine</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
</DOC>